SFPIA
AKBA icon

Stevens First Principles Investment Advisors’s Akebia Therapeutics AKBA Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-850
Closed -$19K – 214
2014
Q3 		$19K Buy
+850
New +$19.5K 0.01% 180

Other funds holding AKBA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stevens First Principles Investment Advisors's AKBA Position: Q4 2014 in Review

Stevens First Principles Investment Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2014, closing a stake of 850 shares — an estimated $19K sold.

Stevens First Principles Investment Advisors first reported a position in AKBA in Q3 2014 and held it in 1 quarter. The position peaked at $19K in Q3 2014. 57 funds tracked by Wall St. Rank hold AKBA as of Q4 2014.

  • Stevens First Principles Investment Advisors reported no remaining Akebia Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 850 Akebia Therapeutics shares in Q4 2014, an estimated $19K.
  • Stevens First Principles Investment Advisors first reported a position in Akebia Therapeutics in Q3 2014 and held it in 1 quarter.
  • Stevens First Principles Investment Advisors's Akebia Therapeutics position peaked at $19K in Q3 2014.
  • 57 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2014.

Based on Stevens First Principles Investment Advisors's 13F filing for Q4 2014, filed 11 Feb 2015.